Coverdells, UGMA/UTMAs, and 529s are among the most popular college-savings vehicles, and savers need to educate themselves on their best option for investing cost-effectively.
Marsico Capital CEO Tom Marsico favors the growth prospects of these biotech companies that are producing novel drugs for unmet medical needs.
September and third-quarter asset-flows data show that investors remain cautious of interest-rate risk and a fully valued stock market, and instead prefer nontraditional bonds and foreign equities.
Vanguard's Fran Kinniry urges yield-seeking investors to use history as a guide and focus on total return instead of taking on equity and credit risk associated with popular income-producing strategies.
Weigh local benefits before ditching your home state's plan.
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
©2012 Morningstar Advisor. All right reserved.